Overview Financials News + Filings Key Docs Ownership Insiders
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
|
|
Edgewise Therapeutics, Inc.
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 08/18/2023 |
4
| Derakhshan Behrad (Chief Business Officer) has filed a Form 4 on Edgewise Therapeutics, Inc.|
Txns:
| Granted 220,000 options to buy
@ $7.08, valued at
$1.6M
|
|
| 08/18/2023 |
4
| MOORE JOHN R (General Counsel) has filed a Form 4 on Edgewise Therapeutics, Inc.|
Txns:
| Granted 200,000 options to buy
@ $7.08, valued at
$1.4M
|
|
| 08/18/2023 |
4
| Carruthers R Michael (CFO) has filed a Form 4 on Edgewise Therapeutics, Inc.|
Txns:
| Granted 200,000 options to buy
@ $7.08, valued at
$1.4M
|
|
| 08/18/2023 |
4
| Russell Alan J (Chief Scientific Officer) has filed a Form 4 on Edgewise Therapeutics, Inc.|
Txns:
| Granted 200,000 options to buy
@ $7.08, valued at
$1.4M
|
|
| 08/18/2023 |
4
| Semigran Marc (Chief Development Officer) has filed a Form 4 on Edgewise Therapeutics, Inc.|
Txns:
| Granted 133,333 options to buy
@ $7.08, valued at
$944k
|
|
| 08/18/2023 |
4
| Donovan Joanne M. (CMO) has filed a Form 4 on Edgewise Therapeutics, Inc.|
Txns:
| Granted 200,000 options to buy
@ $7.08, valued at
$1.4M
|
|
| 08/18/2023 |
4
| KOCH KEVIN (President and CEO) has filed a Form 4 on Edgewise Therapeutics, Inc.|
Txns:
| Granted 600,000 options to buy
@ $7.08, valued at
$4.2M
|
|
| 05/03/2023 |
4
| Derakhshan Behrad (Chief Business Officer) has filed a Form 4 on Edgewise Therapeutics, Inc.|
Txns:
| Sold 1,747 shares
@ $8.9049, valued at
$15.6k
Exercised 5,208 restricted stock units
@ $0 |
|
| 05/03/2023 |
4
| MOORE JOHN R (General Counsel) has filed a Form 4 on Edgewise Therapeutics, Inc.|
Txns:
| Sold 1,897 shares
@ $8.9049, valued at
$16.9k
Exercised 5,208 restricted stock units
@ $0 |
|
| 05/03/2023 |
4
| Carruthers R Michael (CFO) has filed a Form 4 on Edgewise Therapeutics, Inc.|
Txns:
| Sold 1,336 shares
@ $8.9049, valued at
$11.9k
Exercised 5,208 restricted stock units
@ $0 |
|
| 05/03/2023 |
4
| Russell Alan J (Chief Scientific Officer) has filed a Form 4 on Edgewise Therapeutics, Inc.|
Txns:
| Sold 1,602 shares
@ $8.9049, valued at
$14.3k
Exercised 5,208 restricted stock units
@ $0 |
|
| 05/03/2023 |
4
| Donovan Joanne M. (CMO) has filed a Form 4 on Edgewise Therapeutics, Inc.|
Txns:
| Sold 3,254 shares
@ $8.9049, valued at
$29k
Exercised 10,416 restricted stock units
@ $0 |
|
| 05/03/2023 |
4
| KOCH KEVIN (President and CEO) has filed a Form 4 on Edgewise Therapeutics, Inc.|
Txns:
| Sold 3,203 shares
@ $8.9049, valued at
$28.5k
Exercised 10,416 restricted stock units
@ $0 |
|
| 03/07/2023 |
4
| Fox Jonathan C (Director) has filed a Form 4 on Edgewise Therapeutics, Inc.|
Txns:
| Granted 43,731 options to buy
@ $9.43, valued at
$412.4k
|
|
| 03/07/2023 |
3
| Fox Jonathan C (Director) has filed a Form 3 on Edgewise Therapeutics, Inc. |
| 01/03/2023 |
4
| Semigran Marc (Chief Development Officer) has filed a Form 4 on Edgewise Therapeutics, Inc.|
Txns:
| Granted 300,000 options to buy
@ $8.94, valued at
$2.7M
|
|
| 10/05/2022 |
4
| MOORE JOHN R (General Counsel) has filed a Form 4 on Edgewise Therapeutics, Inc.|
Txns:
| Sold 4,730 shares
@ $9.7579, valued at
$46.2k
Exercised 4,730 options to buy
@ $1.93, valued at
$9.1k
|
|
| 09/16/2022 |
4
| Thompson Peter A. (10% Owner) has filed a Form 4 on Edgewise Therapeutics, Inc.|
Txns:
| Bought 484,496 shares
@ $10.32, valued at
$5M
|
|
| 09/16/2022 |
4
| ORBIMED ADVISORS LLC (10% Owner) has filed a Form 4 on Edgewise Therapeutics, Inc.|
Txns:
| Bought 484,496 shares
@ $10.32, valued at
$5M
|
|
| 09/16/2022 |
4
| Novo Holdings A/S (10% Owner) has filed a Form 4 on Edgewise Therapeutics, Inc.|
Txns:
| Bought 484,496 shares
@ $10.32, valued at
$5M
|
|
| 09/08/2022 |
4
| MOORE JOHN R (General Counsel) has filed a Form 4 on Edgewise Therapeutics, Inc.|
Txns:
| Sold 2,379 shares
@ $10.8262, valued at
$25.8k
Sold 2,351 shares
@ $10.992, valued at
$25.8k
Exercised 4,730 options to buy
@ $1.93, valued at
$9.1k
|
|
| 08/10/2022 |
4
| MOORE JOHN R (General Counsel) has filed a Form 4 on Edgewise Therapeutics, Inc.|
Txns:
| Granted 200,000 options to buy
@ $10.39, valued at
$2.1M
|
|
| 08/10/2022 |
4
| Russell Alan J (Chief Scientific Officer) has filed a Form 4 on Edgewise Therapeutics, Inc.|
Txns:
| Granted 220,000 options to buy
@ $10.39, valued at
$2.3M
|
|
| 08/10/2022 |
4
| Carruthers R Michael (CFO) has filed a Form 4 on Edgewise Therapeutics, Inc.|
Txns:
| Granted 200,000 options to buy
@ $10.39, valued at
$2.1M
|
|
| 08/10/2022 |
4
| Derakhshan Behrad (Chief Business Officer) has filed a Form 4 on Edgewise Therapeutics, Inc.|
Txns:
| Granted 200,000 options to buy
@ $10.39, valued at
$2.1M
|
|
| 08/10/2022 |
4
| Donovan Joanne M. (CMO) has filed a Form 4 on Edgewise Therapeutics, Inc.|
Txns:
| Granted 240,000 options to buy
@ $10.39, valued at
$2.5M
|
|
| 08/10/2022 |
4
| KOCH KEVIN (President and CEO) has filed a Form 4 on Edgewise Therapeutics, Inc.|
Txns:
| Granted 550,000 options to buy
@ $10.39, valued at
$5.7M
|
|
| 08/05/2022 |
4
| MOORE JOHN R (General Counsel) has filed a Form 4 on Edgewise Therapeutics, Inc.|
Txns:
| Sold 9,232 shares
@ $9.3069, valued at
$85.9k
Exercised 4,730 options to buy
@ $1.93, valued at
$9.1k
Exercised 4,502 options to buy
@ $0.71, valued at
$3.2k
|
|
| 07/07/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 06/28/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 06/28/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 06/28/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 06/28/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 06/21/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
|
|
|